Regeneron needs revved-up newcomers to backstop vulnerable Eylea—and so far, they're falling short
admin 3rd May 2018 Uncategorised 0Regeneron’s 15% growth in the first quarter came from its aging eye injection Eylea, while its newer drugs came short of expectations. That’s not good—particularly with two potential new rivals threatening that blockbuster lead medication.
More: Regeneron needs revved-up newcomers to backstop vulnerable Eylea—and so far, they're falling short
Source: fierce